In an unprecedented integration of cutting-edge ideas in immunology with clinical neuropathological findings, Neuroinflammation: Mechanisms and Management reviews and synthesizes our knowledge of the inflammatory mediators and cells involved in neurodegenerative diseases. Beginning with a detailed review of the role of biochemical mediators in neuronal loss and the mechanisms of cell death, the distinguished contributors critically examine research on the design of specific pharmacological agents to inhibit defined points in the neuroinflammatory cascade. They also address the molecular, cellular, and therapeutic actions of first generation agents, as well as their potential clinical relevance to AIDS dementia, Alzheimer's disease, amyotropic lateral sclerosis (ALS), Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease, and stroke.

Neuroinflammation: Mechanisms and Management offers a remarkable new synthesis that will play a key role in developingthe molecular targets now emerging in neuropharmacological drug design, and so lead to a new generation of drugs for neurologists to use in the treatment of a wide variety of both acute and chronic neurodegenerative disorders.

Klappentext

An unprecedented review of our current knowledge of the neuroinflammatory mediators and cells involved in neurodegenerative diseases. Beginning with a detailed review of our current concepts of which biochemical mediators are involved in neuronal loss and the mechanisms of cell death, the distinguished contributors critically examine those areas of current research involved in the design of specific pharmacological agents to inhibit at defined points in the neuroinflammatory cascade. They also address the molecular, cellular, and disease model actions of first-generation agents, as well as the potential clinical relevance to AIDS-related dementia, Alzheimer's disease, amyotropic lateral sclerosis (ALS), Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease, and stroke.

Inhalt

Part I. Microglia. Roles of CNS Macrophages in Neurodegeneration, P. L. Wood. Inflammatory Markers in Chronic Neurodegenerative Disorders, with Emphasis on Alzheimer's Disease, D. G. Walker. Inflammatory Markers in Stroke, H. Kato. Microgliosis and Impaired Cognition, D. Giulian and J. Li. Part II. Acute Phase Proteins. Strategies for Inhibition of Complement Activation in the Treatment of Neurodegenerative Diseases, K. Spiegel, M. R. Emmerling, and S. R. Barnum. Inflammatory Mechanisms of Alzheimer's Disease: Basic Research, Clinical Studies, and Future Directions, J. Rogers and W. S. T. Griffin. Part III. Cytokines. Role of IL-1 in Neurodegeneration: Preclinical Findings with IL-1ra and ICE Inhibitors, D. Martin, G. Miller, T. Neuberger, J. Relton, and N. Fischer. Cytokines in Severe Head Injury, L. Ott, C. McClain, S. Scheff, J. Hatton, and B. Young. Neuroimmune Mechanisms in the Treatment of Multiple Sclerosis, R. Lechtenberg. Part IV. Free Radicals. Reactive Oxygen Involvement in Neurodegenerative Pathways: Causes, Consequences, and Potential Management with Nitrone-Based Free Radical Traps, K. Hensley, Q. Pye, T. Tabatabaie, C. A. Stewart, and R. A. Floyd. Utility of the 21-Aminosteroids in Spinal Cord Injury, E. D. Hall. Part V. Miscellaneous Mediators. Role of Cell Adhesion Molecules in Neurological Disorders, D. P. Andrew. The Role of Glial Nitric Oxide in Neurotoxicity and Central Nervous System Diseases, K. M. K. Boje. Inducible Cyclooxygenase (COX-2): A Target for Novel Anti-Inflammatory Drugs, I. W. Rodger and C.-C. Chan. Index.